Kim Helen Susan
SEC insider (Form 3/4/5 filer). CIK 0001422772. Director & 10% Owner at Aktis Oncology, Inc. (AKTS) and 1 other issuer. 5 reported Form 4/5 transactions since Sep 2024; latest on Jan 12, 2026. Located in BOSTON, MA.
Companies Kim Helen Susan has filed insider reports for
- Aktis Oncology, Inc. (AKTS): Director, 10% Owner
- PROTHENA CORP PUBLIC LTD CO (PRTA): Director
Kim Helen Susan
CIK: 0001422772
Transaction Breakdown
Open Market Buys (P)2 (40.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)1 (20.0%)
Compensation grants
Other (G, F, J, C, D, …)2 (40.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (5 total)
- Jan 12, 2026AKTS
Aktis Oncology, Inc.
ConversionIndirect4.9M shares- - Jan 12, 2026AKTS
Aktis Oncology, Inc.
PurchaseIndirect812.5K shares at avg. $18.00$14.6M - Jan 12, 2026AKTS
Aktis Oncology, Inc.
ConversionIndirect134.8K shares- - Jan 12, 2026AKTS
Aktis Oncology, Inc.
PurchaseIndirect22.5K shares at avg. $18.00$406K - May 14, 2025PRTA
PROTHENA CORP PUBLIC LTD CO
AwardDirectStock Option (Right to Buy)
20.2K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jan 12, 2026 |  AKTS Aktis Oncology, Inc. | Conversion | 4,859,370 | - | $0 | Indirect |
| Jan 12, 2026 | AKTS Aktis Oncology, Inc. | Purchase | 812,455 | $18.00 | $14,624,190 | Indirect |
| Jan 12, 2026 | AKTS Aktis Oncology, Inc. | Conversion | 134,842 | - | $0 | Indirect |
| Jan 12, 2026 | AKTS Aktis Oncology, Inc. | Purchase | 22,545 | $18.00 | $405,810 | Indirect |
| May 14, 2025 |  PRTA PROTHENA CORP PUBLIC LTD CO | Award Stock Option (Right to Buy) | 20,183 | - | - | Direct |
1-5 of 5 transactions